IKZF1 (Ikaros) encodes a DNA-binding protein that acts as a master regulatory of hematopoiesis and a tumor suppressor in acute lymphoblastic leukemia (ALL). [1] [2] [3] [4] The deletion and/or mutation of Ikaros is associated with the development of B-cell acute lymphoblastic leukemia (B-ALL) with poor outcome. [5] [6] [7] [8] [9] [10] [11] Ikaros directly associates with components of the histone deacetylase complex (NuRD), HDAC1, HDAC2 and Mi-2.
12-14 Although Ikaros is hypothesized to regulate the transcription of target genes by recruiting the NuRD complex, the mechanism of Ikaros-mediated transcriptional regulation in leukemia is still unknown. Here we use a systems biology approach to determine the mechanism through which Ikaros and HDAC1 regulate gene expression in human B-ALL.
To study the role of Ikaros and Ikaros-HDAC1 complexes in ALL, we determined the genome-wide occupancy of Ikaros and HDAC1 using chromatin immunoprecipitation followed by deep sequencing (ChIP-Seq) in human B-ALL cells (Nalm6 cell line). We identified 12 464 distinct binding sites for Ikaros and 9971 for HDAC1, and these were associated with 6722 and 6182 target genes, respectively ( Figure 1a ). Of these, 12% of the Ikaros-binding sites overlapped by at least 1 bp with 14.6% of the HDAC1-binding sites. The overlapping binding sites correlated with 934 gene targets ( Figure 1a ). ChIP-Seq data for Ikaros and HDAC1 were validated by quantitative chromatin immunoprecipitation (qChIP) analysis of the high-and low-rank ChIP-Seq peak values (Supplementary Figures S1 and S2) . The peak distributions of Ikaros and of HDAC1 relative to target genes revealed that the binding of both proteins is highly enriched within ± 3 kb from transcriptional start sites (Figure 1b) .
We analyzed the effect of Ikaros and HDAC1 DNA binding on the surrounding chromatin. First, the genome-wide distribution of histone H3 trimethylation at lysine 4 (H3K4me 3 ), lysine 27 (H3K27me 3 ), lysine 36 (H3K36me 3 ), or lysine 9 (H3K9me 3 ), or acetylated at lysine 9 (H3K9ac) was determined by ChIP-Seq experiments in Nalm6 cells. ChIP-Seq data for histone modifications were validated by qChIP analysis of the high-and lowrank ChIP-Seq peak values (Supplementary Figures S3-S7 ). Next, we analyzed the distribution of chromatin modifications relative to (1) Ikaros peaks; (2) Ikaros-HDAC1 overlapped peaks; and (3) HDAC1 peaks. Most of the Ikaros and HDAC1 binding occurs within the promoters of target genes (Figure 1b) . Thus, we compared the epigenetic changes that we observed in chromatin surrounding Ikaros, Ikaros-HDAC1 and HDAC1 peaks (Figures 1c-e) , which are located within the promoter region, to epigenetic markers present in chromatin surrounding promoters across the genome, regardless of Ikaros and/or HDAC1 occupancy (Figure 1f) .
We found that unique epigenetic changes are associated with Ikaros, Ikaros-HDAC1 and HDAC1 peaks. Ikaros peaks are associated with the presence of H3K4me 3 , H3K9me 3 and H3K9ac histone modifications (Figure 1c ). Ikaros-HDAC1 overlapped peaks correlated with a different chromatin environment that is characterized by the very strong presence of H3K4me These results indicate that the binding of Ikaros, Ikaros-HDAC1 or HDAC1 is each associated with a distinct characteristic chromatin change that likely affects the expression of target genes. The specific distribution of histone modifications around Ikaros, Ikaros-HDAC1 or HDAC1 peaks were similar, regardless of whether these peaks were localized within promoter regions or other regions across the genome (Supplementary Figures  S8-S10) . Most of the specific epigenetic changes occur within 1 kb of the center of the Ikaros, Ikaros-HDAC1 or HDAC1 peaks. This suggests that binding of these proteins has a direct effect on chromatin remodeling and the observed epigenetic changes.
Our analysis demonstrates a strong association between HDAC1 occupancy and H3K27me 3 (Supplementary Table S1 ). This is particularly pronounced at promoter regions-85% of all promoters with H3K27me 3 showed HDAC1 binding (Figure 1g ). This suggests that HDAC1 occupancy is the major determinant of the H3K27me 3 marker. Further analysis demonstrates Ikaros-HDAC1 occupancy at 21% of all promoters with H3K27me 3 in leukemia cells (Figure 1g ). This suggests that Ikaros binding to promoters of its target genes can result in H3K27me 3 via recruitment of HDAC1. These results show the importance of Ikaros' recruitment of HDAC1 in determining the global epigenetic signature in leukemia. We tested whether histone deacetylase activity is required for the formation of H3K27me 3 in Nalm6 cells. Treatment of Nalm6 cells with the histone deacetylase inhibitor trichostatin resulted in strong reduction of H3K27me 3 by western blot (Figure 1h ), suggesting that histone deacetylase activity is essential for the presence of H3K27me 3 . These results demonstrate an essential role for histone deacetylase in the formation of H3K27me 3 in B-ALL. ChIP-Seq analysis of the epigenetic signature around Ikaros occupancy led to the hypothesis that DNA binding of Ikaros or Ikaros-HDAC1 complexes alters the transcription of their respective target genes by induction of distinct epigenetic changes. To test this hypothesis, we analyzed the effect of increased Ikaros expression on chromatin remodeling at promoters of genes that are regulated by Ikaros-only or by Ikaros-HDAC1 complexes. Recently, we reported that Ikaros represses the transcription of a large number of genes that promote cell cycle progression in leukemia. 15 The epigenetic signatures at promoters of the cell cycle-promoting genes CDC7 and ANAPC7 (Ikaros-only targets), and CDC2 and ANAPC1 (Ikaros-HDAC1 targets) were compared in Nalm6 cells transduced with Ikaros or empty vector (control) using serial qChIP assays. Results showed that increased Ikaros expression is associated with unchanged H3K27me 3 , increased H3K9me Next, we studied how Ikaros loss-of-function or gain-offunction affects the transcriptional regulation and epigenetic signature of Ikaros target genes in primary high-risk B-ALL cells. In high-risk B-ALL, Ikaros function as a transcriptional regulator is severely impaired due to the deletion of one Ikaros allele and/or functional inactivation of Ikaros protein by Casein Kinase II (CK2) phosphorylation. 15 Inhibition of CK2 has been shown to restore Ikaros activity as transcriptional regulator, resulting in transcriptional repression of Ikaros target genes that promote cell cycle progression. 15 We analyzed the epigenetic signature at promoters of Ikaros and Ikaros-HDAC1 Figure 11) .
In summary, our data reveal the mechanism by which chromatin remodeling and target gene expression are regulated by Ikaros alone and in complex with HDAC1 in B-ALL (Figure 2e ). These data suggest that Ikaros can repress transcription of its target genes by inducing the formation of repressive chromatin via two distinct mechanisms: (1) direct Ikaros binding resulting in the formation of heterochromatin due to increased H3K9me 3 and reduced H3K9ac; or (2) Ikaros recruitment of HDAC1, where the most prominent change is a strong increase in H3K27me 3 along with reduced H3K9ac. In high-risk B-ALL, Ikaros ability to regulate chromatin remodeling of its target genes is impaired. In high-risk B-ALL with deletion of one Ikaros allele, inhibition of CK2 restores Ikaros-mediated epigenetic repression of the cell cycle-promoting genes. These data suggest that the ability to regulate chromatin remodeling is an essential part of Ikaros tumor-suppressor function. These studies provide new insight into the epigenetic regulation of gene expression in B-ALL and a rationale for the use of CK2 inhibitors as a novel treatment. Several phenotypic, molecular and chromosomal markers of chronic lymphocytic leukemia (CLL) cells have been identified that are significantly associated with patient prognosis. [1] [2] [3] [4] [5] [6] However, these markers used singularly are inaccurate predictors of outcome for individual patients. Recent efforts have focused on combining markers to predict either treatment-free survival (TFS) 4, 7, 8 or overall survival (OS), [9] [10] [11] however, further effort is worthwhile to determine how to combine prognostic parameters, optimize risk stratification, simplify calculations and/or identify new prognostic variables.
Herein analyzing data from a cohort of Binet A patients, enrolled in a prospective multicenter observational study, we developed a weighted, multivariate score (progression-risk score (PRS)) integrating clinical, laboratory and biological parameters independently associated with TFS. The PRS was subsequently validated using an external cohort of CLL patients from the Mayo Clinic, Minnesota, USA.
We analyzed data from 480 newly diagnosed CLL patients enrolled in the O-CLL1-GISL protocol (clinicaltrial.gov identifier: NCT00917540). Of these, 337 cases with available biological (CD38, ZAP-70, IGHV mutational status and fluoresent in situ hybridization (FISH)) and clinical/laboratory parameters (sex, age, absolute lymphocyte count, Rai-modified stage, lactate dehydrogenase (normal range, 313-618 IU/l) and β2-microglobulin level (normal range, 0.6-2.0 mg/l), 11 were included in this analysis (see Supplementary Methods).
Factors independently associated with TFS were included in the PRS. To account for differences in the magnitude of the association between individual independent factors and TFS, we assigned a weighted-risk score to each factor based on ranges of their corresponding hazard ratios (HR) (that is, 1 point for HR 1.1-1.9; 2 points for HR 2.0-2.9 and so on). 9 The total risk score was then calculated by summing the ratings of each individual factor. Risk groups were identified combining risk categories with a non-statistically different TFS (see Supplementary Methods).
Baseline patient features of the training cohort are listed in Supplementary Table S1 . Patients with Rai stage I and II were grouped for analysis according to convention. 12 Given the limited number of patients with del(11q23) and del(17p13), cytogenetic abnormalities identified by FISH were clustered in three risk groups (that is, low risk (del(13q14) and normal), intermediate risk (trisomy 12) and high risk (del(11q23) and del(17p13)). After a median 42 months follow-up (range, 6-82 months), 84/337 (24.9%) cases required treatment.
In multivariate analysis, Rai stage I-II, absolute lymphocyte count ⩾ 10 × 10 9 /l, elevated β2-microglobulin levels, and IGHV-UM remained associated with shorter TFS (Table 1 ). The multivariate model was confirmed by bootstrap resampling (data not shown). Considering the HR of the independent factors, a risk score was assigned to each marker (Table 1) ; the total risk score was defined as the sum of the risk scores of the four individual parameters (range, 0-7). According to the predefined criteria (Supplementary  Table S2 ), three different risk categories for TFS were determined: low (score 0-2), intermediate (score [3] [4] [5] and high risk (score 6-7; Supplementary Table S3). Accepted article preview online 9 December 2015; advance online publication, 19 January 2016
